56463 Collaboration: Novel Drug Treatment For Cancer With Unprecedented Efficacy and Safety


A company based in Turkey offers patented technology for cancer therapy. The treatment is targeted to a fundamental vulnerability of tumour cells identified by the founder of company and has been shown in phase II clinical investigations to safely eliminate tumour cells from patients irrespective of organ of origin and stage of tumour. Joint venture, technical cooperation and other agreements will be explored towards regulatory approval and marketing. Licensing is possible for certain areas.
Further information and full details of the contracting authority are available on request.
0 days left till deadline

Enquire about this opportunity:

If you are a member then please login to the site to have the full detail sent to you automatically.
If you are not a member, please complete the form below to request further information.

Your Full Name*
Company Name*
Email*
Phone*
Address
Postcode / Zip*
Country
Comment:
(please enter your interest
or suitability for this opportunity)
Security phrase
(NOT case sensitive)
*
* Denotes a required field

myM-link Video

Events

The Collaborative Healthcare Leadership Programme

20th February 2012

Faced with diminishing resource and budget, Leaders within the NHS are having...

Read in full >

Pre-clinical Evaluation in Drug Development

7th March 2012

The aim of this unique short course is to provide a detailed insight into the...

Read in full >

Clinical Evaluation of Medical Technology

13th March 2012

The course is designed to help regulatory professionals understand the fundam...

Read in full >

Management of Regulatory Affairs & its Contribution to the Medical Technology Lifecycle

12th June 2012

The course is designed to provide students with an understanding of the skill...

Read in full >